Braidwell LP Legend Biotech Corp Transaction History

Braidwell LP

$1.79 Billion
Q4 2024

A detailed history of Braidwell LP transactions in Legend Biotech Corp stock. As of the latest transaction made, Braidwell LP holds 2,977,951 shares of LEGN stock, worth $101 Million. This represents 5.43% of its overall portfolio holdings.

Number of Shares

2,977,951

Previous 1,541,551 93.18%

Holding current value

$101 Million

Previous $75.1 Billion 99.87%

% of portfolio

5.43%

Previous 2.13%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$32.49 - $50.28 $46.7 Million - $72.2 Million	1,436,400 Added 93.18%	2,977,951 $96.9 Million
Q3 2024 Nov 14, 2024	SELL	$43.55 - $59.88 $5.58 Million - $7.67 Million	-128,169 Reduced 7.68%	1,541,551 $75.1 Billion
Q2 2024 Aug 14, 2024	BUY	$39.5 - $57.22 $16.8 Million - $24.4 Million	425,925 Added 34.24%	1,669,720 $74 Billion
Q1 2024 May 15, 2024	BUY	$55.06 - $69.99 $37.5 Million - $47.7 Million	681,195 Added 121.08%	1,243,795 $69.8 Billion
Q4 2023 Feb 14, 2024	SELL	$57.25 - $69.74 $18.1 Million - $22.1 Million	-316,964 Reduced 36.04%	562,600 $33.9 Billion
Q3 2023 Nov 14, 2023	BUY	$63.16 - $76.5 $20.4 Million - $24.7 Million	323,263 Added 58.11%	879,564 $59.1 Billion
Q2 2023 Aug 14, 2023	SELL	$46.28 - $75.01 $2.11 Million - $3.41 Million	-45,500 Reduced 7.56%	556,301 $38.4 Billion
Q1 2023 May 15, 2023	SELL	$43.42 - $57.37 $2.44 Million - $3.23 Million	-56,300 Reduced 8.55%	601,801 $29 Billion
Q4 2022 Feb 14, 2023	BUY	$38.8 - $55.46 $25.5 Million - $36.5 Million	658,101 New	658,101 $32.9 Billion

Others Institutions Holding LEGN

# of Institutions

232

Shares Held

86.1M

Call Options Held

260K

Put Options Held

387K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $5.69B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account